Drugs / SL19+22
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05206071 | May 2021 → Dec 2023 | non-Hodgkin lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SL19+22 | “SL19+22 injection is a CAR-T product independently developed by Senlang that targets both CD19 and CD22.” NCT05206071 ↗ |
| Modality | Cell therapy | “SL19+22 injection is a CAR-T product” NCT05206071 ↗ |
| Target | CD19 | “targets both CD19 and CD22” NCT05206071 ↗ |
| Target | CD22 | “targets both CD19 and CD22” NCT05206071 ↗ |